Senzime AB (publ) (SNZZF)
- Previous Close
0.6650 - Open
0.6650 - Bid 0.6230 x --
- Ask 0.7020 x --
- Day's Range
0.6650 - 0.6650 - 52 Week Range
0.2510 - 0.9650 - Volume
3,000 - Avg. Volume
2,112 - Market Cap (intraday)
80M - Beta (5Y Monthly) 0.56
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1200 - Earnings Date Aug 26, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. It offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance to measure the tissue's opposition to carrying an alternating electrical current. The company has a strategic connectivity and licensing agreement with Masimo to develop, manufacture, market, and distribute products that can connect to the Masimo Root patient monitoring system and related digital hub for data transmission to hospital electronic patient journals; license agreement with Fukuda Denshi Co. Ltd. to license TetraGraph technology; and license agreement with CoreSpiron (Henan) Co Ltd. to manufacture and sell ExSpiron system. Senzime AB (publ) was incorporated in 1999 and is headquartered in Uppsala, Sweden.
www.senzime.comRecent News: SNZZF
Performance Overview: SNZZF
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SNZZF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SNZZF
Valuation Measures
Market Cap
80.00M
Enterprise Value
69.84M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
17.78
Price/Book (mrq)
2.35
Enterprise Value/Revenue
17.90
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-21.19%
Return on Equity (ttm)
-39.40%
Revenue (ttm)
40.59M
Net Income Avi to Common (ttm)
-131.28M
Diluted EPS (ttm)
-0.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
116.86M
Total Debt/Equity (mrq)
3.18%
Levered Free Cash Flow (ttm)
-67.63M
Company Insights: SNZZF
SNZZF does not have Company Insights